Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ABL2 | P42684 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 10/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 10/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | USP2 | O75604 | 4/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.39 |
| ▸ | TSHR | P16473 | 6/20 | 0.39 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30813541 | 0.93 | BTK (0.46) | SRCABL1EGFRABL2PDE9A | |
| SCHEMBL30813419 | 0.92 | EPHX2 (0.44) | RETKDRSRCABL1EGFR | |
| SCHEMBL27217814 | 0.90 | RET (0.40) | RETKDRSRCABL1EGFR | |
| SCHEMBL30813475 | 0.90 | RET (0.40) | RETKDRSRCABL1EGFR | |
| SCHEMBL27217953 | 0.90 | CYP1A2 (0.42) | EGFRCYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL21903703 | 0.88 | CYP1A2 (0.38) | CYP1A2CYP3A4CYP2C19CYP2D6CLK4 | |
| SCHEMBL27217855 | 0.84 | CYP1A2 (0.46) | CYP1A2CYP3A4CYP2C19CYP2D6CLK4 | |
| SCHEMBL27217885 | 0.84 | BTK (0.45) | SRCABL1EGFRABL2EPHX2 | |
| SCHEMBL27217920 | 0.84 | ERBB2 (0.44) | EGFRPDE9AKMT2ABTK | |
| SCHEMBL30813648 | 0.84 | EPHX2 (0.43) | RETKDRSRCABL1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| WO-2024059200-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | RET 2117/4885KDR 4752/4885SRC 1597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.